SAN FRANCISCO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the U.S. launch of its next-generation Zio® monitor and enhanced Zio® long-term continuous ...

Rhythm (Nasdaq: IRTC) today shared new findings supporting the use of its long-term continuous monitoring (LTCM) service.

Real-world data across more than 1 million patients published in Heart Rhythm show that 24–48-hour monitoring can miss actionable arrhythmias and ...

The market has left medical device stocks in the dust, but heart monitor maker iRhythm Technologies is proving an exception.

Zio ECG monitoring system is the only fourteen-day cardiac monitoring service in its category to receive Japanese regulatory approval as an improved device without a clinical trial Zio long-term ...

In recent announcements, iRhythm Technologies increased its revenue guidance for fiscal year 2025 to between US$735 million and US$740 million and reported third quarter sales growth to US$192.88 ...

iRhythm Technologies IRTC recently announced initial research findings on the post-market, real-world performance of the Zio monitor, IRTC’s next-generation Zio long-term continuous monitoring (LTCM) ...

Findings in a younger, commercially insured population build on Medicare-based CAMELOT results, expanding the generalizability of Zio LTCM's clinical impact across patient groups. Latest data showed ...

iRhythm is launching its next generation long-term ambulatory cardiac monitor in the U.S. The new Zio monitor is a prescription-only ECG monitor, which is an integral part of the Zio LTCM service. The ...